Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about the latest bladder cancer clinical trial results and treatment advances presented at the 2025 European Society for Medical Oncology (ESMO) conference in this comprehensive medical education video. Discover key findings from three pivotal studies that are reshaping bladder cancer treatment protocols, including KEYNOTE 905's breakthrough results showing perioperative enfortumab vedotin plus pembrolizumab significantly improved event-free survival and overall survival in cisplatin-ineligible muscle-invasive bladder cancer patients compared to cystectomy alone. Explore the IMVIGOR011 trial data demonstrating how adjuvant atezolizumab enhanced disease-free survival and overall survival in circulating tumor DNA-positive muscle-invasive bladder cancer patients versus placebo treatment. Examine the RC48-C016 study results revealing that the combination of disitamab vedotin (HER2 antibody-drug conjugate) plus toripalimab (PD-1 inhibitor) substantially improved progression-free survival and overall survival compared to standard gemcitabine plus platinum chemotherapy in first-line HER2-positive metastatic urothelial carcinoma. Gain insights into how these clinical developments are influencing current treatment paradigms and patient care strategies in genitourinary oncology practice.
